This retrospective study examined outcomes of hormone receptor-positive (HR to November 2016 in patients treated with palbociclib after prior treatment with everolimus. Progression-free survival (PFS) was defined as the time from initiation of palbociclib to the date of progression as determined by the treating physician based on radiologic, biochemical, and/or clinical criteria. Response rates were determined on the basis of available radiologic data. Objective response rate (ORR) was defined as the rate of any complete or partial responses; clinical benefit rate (CBR) was the rate of complete response, partial response, or stable disease for at least 24 weeks. Results: Twenty-three patients with a mean (range) age of 68 (42-81) years were identified. Kaplan-Meier estimate showed median PFS of 2.9 months (95% confidence interval, 2.1-4.2); ORR was 0 of 23 and CBR was 4 (17.4%) of 23. In the PALOMA-3 trial, median PFS, ORR, and CBR of palbociclib cohort were 9.5 months (95% confidence interval, 9.2-11.0), 19%, and 67%, respectively. Conclusion: There is a limited clinical activity of palbociclib combinations after progression with everolimus combination therapy. Further studies are necessary to confirm these findings. 
Introduction
Endocrine therapy forms the backbone of anticancer therapy in hormone receptor-positive (HR þ ) human epidermal growth factor receptor nonamplified (HER2 À ) metastatic breast cancer (MBC).
Everolimus, an mTOR inhibitor, when combined with exemestane, a steroidal aromatase inhibitor (AI), improves progression-free survival (PFS) compared to exemestane alone in HR þ HER2 À MBC in patients whose disease failed to respond to nonsteroidal AI. 1 Thus, everolimus in combination with exemestane has been approved for treatment of HR þ HER2 À MBC after failure of treatment with a nonsteroidal AI. The cyclin-dependent kinase (CDK) 4/6 inhibitors palbociclib, ribociclib, and abemaciclib, each in combination with an AI, have been shown to be efficacious against HR þ HER2
À MBC as first-line therapy and thus have been approved for treatment as initial endocrine-based therapy in breast cancer. [2] [3] [4] Similarly, the PALOMA-3 trial showed that palbociclib in combination with fulvestrant, a selective estrogen receptor degrader, was associated with significantly better PFS compared to fulvestrant alone in HR þ HER2 À MBC that had progressed while the patient received at least one line of endocrine therapy. 5 This trial excluded patients who had previously received everolimus because multiple preclinical studies have suggested that interactions exist between the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/ mammalian target of rapamycin (mTOR) pathway and the cyclin D/CDK4/6/Rb pathway. [6] [7] [8] [9] [10] Currently there are few clinical data on effectiveness of CDK4/6 inhibitors in patients previously treated with mTOR inhibitors. With an increasing number of therapeutic options for HR þ HER2 À MBC patients in both first and later lines, it is important to determine the best sequence of therapies. The objective of this study was to examine the clinical outcomes of HR þ
HER2
À MBC patients with prior exposure to everolimus who received palbociclib-based therapy.
Patients and Materials
This study was approved by the institutional review board of Roswell Park Comprehensive Cancer Center and is a singleinstitution retrospective review of HR þ
HER2
À MBC patients who received treatment at the institute from January 2014 to November 2016. Women were included if they had been treated with palbociclib-based therapy after prior treatment with everolimus. Women who received everolimus for less than 1 month or palbociclib for fewer than 14 days were excluded. PFS was defined as the time from the initiation of palbociclib to the date of progression as determined by the treating physician based on available radiologic, biochemical, and/or clinical information. Best overall response rates were determined on the basis of available radiologic data. Objective response rate (ORR) was defined as the best overall response of complete response or partial response. Clinical benefit rate (CBR) was defined as complete response, partial response, or stable disease of at least 24 weeks. Kaplan-Meier estimates were used for survival analysis. R software was used for statistical analysis and survival curve generation (R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org/).
Results
Of 28 patients obtained from the initial computer-based query in the electronic medical record, only 23 patients were eligible for the final data collection and analysis. Of 5 patients excluded, 3 received palbociclib for less than 14 days, 1 received everolimus for less than a month, and 1 was found to have a HER2 amplified MBC on repeat biopsy; they thus were ineligible for the study. Median age of the patients was 68 years (range, 42-81 years), and all were women. A total of 95% of the women were postmenopausal, and 83% had visceral metastases (ie, lung, liver, brain, pleural, or peritoneal involvement). Median (range) estrogen receptor Allred score from the most recent biopsy before start of palbociclib was 8 (5-8). Ninety-five percent of the women had more than 2 lines of prior endocrine therapy including both adjuvant/neoadjuvant therapies and treatment for advanced disease. A total of 82% of women showed prior sensitivity to endocrine therapy. This was defined as documented clinical benefit from at least one previous endocrine therapy (including everolimus-based therapy) in the metastatic setting or treatment with at least 24 months of adjuvant therapy before disease recurrence. Overall, 82% of women received prior chemotherapy, 84% of which were in the metastatic setting. Median (range) duration of everolimus therapy was 6 (1.7-34.5) months. Everolimus therapy was terminated in 78% women as a result of disease progression, while in the remaining patients it was stopped because of intolerance or other reasons. The median number of chemotherapy agents or hormone therapies between everolimus and palbociclib was 1 (range, 0-6). Table 1 compares various parameters of the study cohort with the historical palbociclib cohort of the PALOMA-3 trial.
At the time of data extraction, the disease of 21 patients had progressed while receiving palbociclib-based therapy; there were no treatment discontinuation due to toxicity. Seventeen patients were deemed to have progressive disease by their treating physicians on the basis of computed tomographic scan, bone scan, or positron emission tomographic scan results. The remaining 4 patients were deemed to have progressive disease on the basis of relevant laboratory results (worsening hypercalcemia in 2 patients with extensive bone metastases, worsening liver function in 2 patients with extensive liver metastases, increasing tumor markers in all patients) and worsening clinical assessment. Kaplan-Meier estimate of survival of the study cohort showed a median PFS of 2.9 months (95% confidence interval [CI], 2.1-4.2) ( Figure 1) ; ORR was 0 of 23 and CBR 4 (17.4%) of 23 (Table 2) . Median PFS, ORR, and CBR of the palbociclib cohort of the PALOMA-3 trial were 9.5 months (95% CI, 9.2-11.0), 19%, and 67%, respectively. 5 Median overall survival of the study cohort had not been reached at the time of analysis and was > 19.8 months (95% CI, 7.2->19.8) (Figure 2 ).
Discussion
The PALOMA-3 trial was a multicenter, double-blind, randomized phase 3 trial that assessed the efficacy of palbociclib plus fulvestrant compared to fulvestrant alone in HR þ HER2 À MBC patients previously treated with endocrine therapy. 5 Eligible patients were women aged 18 years or older with any menopausal status, Eastern Cooperative Oncology Group performance status of 0-1, with biopsy-proven HR þ HER2 À MBC that had progressed on previous endocrine therapy, and had measurable or bone only metastatic diseases. Prior treatment with everolimus or a PI3K/mTOR pathway inhibitor was an exclusion criterion. Median progression-free survival was 9.5 months (95% CI, 9.2-11.0) in the fulvestrant plus e1402 -Clinical Breast Cancer December 2018
Palbociclib Combinations in Breast Cancer palbociclib group and 4.6 months (95% CI, 3.5-5.6) in the fulvestrant plus placebo group (hazard ratio ¼ 0.46; 95% CI 0.36-0.59; P < .0001). Our study showed that palbociclib is associated with a short PFS of 2.9 months (95% CI, 2.1-4.2) and with no objective response among HR þ HER2 À MBC with prior treatment with everolimus. The main weakness is that we are comparing our small retrospective cohort with a cohort treated under the PALOMA-3 protocol, which is a randomized phase 3 trial. Assessment of response was less standardized and did not use Response Evaluation Criteria in Solid Tumors. Compared to the PALOMA-3, the present cohort is older, less fit, has more visceral metastases, and has received both more lines of endocrine and chemotherapy in the metastatic setting. Despite having a short PFS of 2.9 months, the study cohort has a median overall survival of more than 19.8 months, which shows that their disease continued to be responsive to further therapies and that the patients were not in a terminal stage of disease when initiating palbociclib-based therapy. Finally, not all patients in the cohort received fulvestrant as the endocrine therapy component. Some of the patients received AI in combination with palbociclib because of patient or physician preference. Fulvestrant has a different mechanism of action than AI. The data suggest that it is potentially more effective than AI in patients with ESR1 mutation, a common mutation thought to cause resistance to endocrine therapy. 11 This variance adds to the limitation of the study. Despite the study's limitations, the outcome data of palbociclib after everolimus from our study are novel and the results are hypothesis generating. A prospective nonrandomized single-arm study of the efficacy of palbociclib plus fulvestrant after everolimus in France showed a median PFS after palbociclib combination to be 5.8 months (95% CI, 3.9-7.3). 12 A total of 26.7% had partial response, while 45% had stable disease as best response. No CBR was reported. Both our results and the published results from the French study suggest that tumors acquiring resistance to the PI3K/Akt/mTOR pathway inhibition may have cross-resistance to CDK4/6 inhibition. Multiple preclinical studies have suggested interactions between the PI3K/Akt/mTOR pathway and the cyclin D/CDK4/6/Rb pathway. Expression of Cyclin D is controlled posttranscriptionally via the PI3K/Akt/mTOR dependent pathway. 10 mTOR inhibition in various cell lines has been associated with increased activity of p16 INK4a , leading to decreased activity of the cyclin D/CDK4/6 complex, ultimately causing cell cycle arrest. [6] [7] [8] [9] However, CDK4/6 inhibition has been shown to have a synergistic effect in producing tumor regression in combination with PI3K inhibitor in breast cancer cell lines with otherwise intrinsic or acquired resistance to PI3K inhibitors. 13 Thus, there appears to be a complex interaction between aberrations in the PI3K/Akt/mTOR and the cyclin D/CDK4/6 pathways causing cell proliferation and decreased apoptosis. In recent years, everolimus, palbociclib, ribociclib, and abemaciclib in combination with endocrine therapy have improved the outcomes of HR þ HER2 À MBC patients. 
HER2
À MBC, it is important to understand how to use these drugs clinically to obtain best clinical benefit for patients. Understanding appropriate sequence of therapies in increasingly complex decision trees for treatment of these patients is necessary in order to delay emergence of resistance, to enhance clinical benefit, and to decrease toxicities. In the future, the choices might become more difficult, with results from early-stage clinical trials evaluating the combination of mTOR inhibitor, CDK4/6 inhibitor, and an AI (NCT02871791, phase 1, palbociclib þ everolimus þ exemestane; NCT02732119, phase 1/2, ribociclib þ everolimus þ exemestane; NCT01857193, phase 1b, ribociclib þ everolimus þ exemestane).
Currently there is no active effort to determine the optimal sequence of these agents, leaving clinicians to make choices based on limited data and toxicity profiles. We designed our study to investigate the clinical outcome of the CDK4/6 inhibitor palbociclib in HR þ HER2 À MBC after patients had been treated with everolimusbased therapy.
Conclusion
This study has shown that palbociclib-based therapy is associated with a short PFS and poor response rate in HR þ
HER2
À heavily pretreated MBCs with prior treatment with everolimus. The results from a recent French study also report short PFS with palbociclib combinations after disease progression while receiving everolimus combination therapy. These results indicate a PFS shorter than that reported in the PALOMA-3 study. These results suggest that there might be limited clinical benefit with a palbociclib combination after previous treatment with an everolimus combination. With such a small cohort it is unclear whether some patients continue to receive significant benefit from this therapy. Larger prospective studies comparing different sequences of therapies should be conducted to identify biomarkers and define optimal sequences of therapy in this patient population.
Clinical Practice Points
The PALOMA-3 trial is a phase 3 multicenter study that showed significant clinical benefit of palbociclib-based therapy in second line among HR þ HER2 À everolimus-naive MBC. As therapy options have increased for HR þ MBCs, it is important to find an optimal sequence of therapies. We performed a retrospective study to assess the clinical outcome of palbociclibbased therapy among HR þ MBCs with prior everolimus treatment.
With palbociclib combinations, median PFS was short, and ORR and CBR were poor in our cohort, thus suggesting that palbociclib-based therapy is associated with limited clinical outcomes among heavily pretreated, everolimus-exposed HR þ MBCs, and supports the current practice of using palbociclibbased therapy before everolimus in this sequence. Further studies are required to confirm and build on this finding.
